Biocompatibility testing is often where teams want to move quickly. But testing too early, or testing without a clear strategy, can create expensive problems. The better question is not, “Which tests do we need?” It is, “What biological risks do we need to evaluate, and what evidence is already available?”
Before you send samples to the lab, confirm these five items:
The device configuration is representative. Testing should generally be performed on a representative finished device or a justified worst-case configuration. If the material, coating, adhesive, sterilization method, packaging, manufacturing process, or cleaning process changes after testing, the previous data may no longer fully support the final product.
Contact type and duration are clear. A limited-contact surface device, an externally communicating device with blood contact, and a long-term implant raise very different questions. Contact classification helps determine which biological endpoints are relevant.
Existing evidence has been reviewed. Prior testing, supplier data, material history, literature, predicate device information, chemical characterization, toxicological risk assessment, and manufacturing knowledge may all help define the remaining gaps.
Chemistry has been considered. Extractables, leachables, degradation products, residuals, and processing aids can be central to the biological risk profile. Chemical characterization can help identify substances that may require toxicological evaluation and may reduce reliance on certain biological tests when supported by a strong rationale.
The lab and methods fit the regulatory need. Extraction conditions, sample preparation, GLP requirements when applicable, acceptance criteria, and final reporting expectations should be aligned before the study begins.
Why “just run the tests” can backfire
Testing without a biological evaluation plan can create confusing results. A team may learn too late that the wrong test article was used, that extraction conditions were not appropriate, that a required endpoint was missed, or that the report does not explain how the data supports the device’s intended use.
In those cases, the team may not simply need more data. It may need to repeat work that could have been avoided with better planning.
What a stronger approach looks like
A stronger approach starts with the biological evaluation plan. The plan should describe the device, materials, patient contact, manufacturing considerations, available evidence, identified risks, and remaining questions. From there, testing becomes more focused.
This does not mean testing can always be avoided. It means testing is selected because it answers a defined gap.
Strategy before testing
Biocompatibility testing is most valuable when it is connected to a broader biological safety strategy. When the strategy is built first, the test plan becomes more focused, the data is easier to defend, and the team is less likely to lose time to avoidable retesting.
Need guidance on preclinical strategy, biological evaluation, or study planning? Contact TEM Biomed to discuss your development program.
